Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $20.91 and last traded at $22.26, with a volume of 920471 shares traded. The stock had previously closed at $21.91.
Wall Street Analysts Forecast Growth
CLDX has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday. They set a "buy" rating and a $44.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $60.22.
Get Our Latest Analysis on Celldex Therapeutics
Celldex Therapeutics Price Performance
The stock has a 50 day simple moving average of $24.70 and a 200-day simple moving average of $29.79. The firm has a market cap of $1.51 billion, a PE ratio of -8.83 and a beta of 1.60.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its stake in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 878 shares during the last quarter. KBC Group NV increased its position in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 495 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Celldex Therapeutics during the fourth quarter valued at $81,000. AlphaQuest LLC increased its position in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Celldex Therapeutics during the fourth quarter valued at about $121,000.
About Celldex Therapeutics
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Read More
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
